Literature DB >> 9879686

Molecular analysis of a de novo mutation for spinocerebellar ataxia type 6 and (CAG)n repeat units in normal elder controls.

M Shizuka1, M Watanabe, Y Ikeda, K Mizushima, K Okamoto, M Shoji.   

Abstract

Spinocerebellar ataxia type 6 (SCA6) is an autosomal dominant spinocerebellar degenerative disease caused by CAG repeat expansions in the human alpha1A voltage-dependent calcium channel subunit gene (CACNL1A4). We analyzed 15 SCA6 patients in 14 unrelated Japanese families and 52 healthy Japanese aged over 74 years. Sequence analysis was performed to determine the correct number of CAG repeats. The expanded CAG repeat number was 23.6+/-2.1 (mean+/-S.D., n=15) with a range of 20-29, and the shortest expanded allele was 20 repeats. Moreover, the analysis of normal subjects revealed that the CAG repeat number of normal alleles was 12.3+/-1.9 (n=104) with a range of 7-18. We concluded that the normal range of CAG repeats in the CACNL1A4 gene is 18 or less, and that the disease range is 20 or more. Of 15 SCA6 patients, three sporadic cases were observed. In one male patient with 26 CAG repeats, the CAG repeat numbers of his parents were within normal range. His expanded allele was considered to be caused by an expansion of a normal allele from his mother (14 or 17 repeats). This is the first SCA6 case which was genetically proven to occur due to a de novo mechanism, suggesting that larger CAG repeats of normal alleles in the CACNL1A4 gene may be unstable and result in full expansion.

Entities:  

Mesh:

Year:  1998        PMID: 9879686     DOI: 10.1016/s0022-510x(98)00270-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Chaperone-like N-methyl peptide inhibitors of polyglutamine aggregation.

Authors:  Jennifer D Lanning; Andrew J Hawk; Johnmark Derryberry; Stephen C Meredith
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

2.  Post-zygotic de novo trinucleotide repeat expansion at spinocerebellar ataxia type 7 locus: evidence from an Indian family.

Authors:  Uma Mittal; Sanghamitra Roy; Satish Jain; Achal K Srivastava; Mitali Mukerji
Journal:  J Hum Genet       Date:  2005-03-05       Impact factor: 3.172

3.  Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect.

Authors:  Gregory D Darnell; JohnMark Derryberry; Josh W Kurutz; Stephen C Meredith
Journal:  Biophys J       Date:  2009-10-21       Impact factor: 4.033

4.  Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).

Authors:  Giovanni Stevanin; Alexis Brice
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 5.  Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.

Authors:  Swati Naphade; Kizito-Tshitoko Tshilenge; Lisa M Ellerby
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

6.  The Etiologies of Chronic Progressive Cerebellar Ataxia in a Korean Population.

Authors:  Ji Sun Kim; Soonwook Kwon; Chang Seok Ki; Jinyoung Youn; Jin Whan Cho
Journal:  J Clin Neurol       Date:  2018-07       Impact factor: 3.077

Review 7.  Advances in Modeling Polyglutamine Diseases Using Genome Editing Tools.

Authors:  Marianna Karwacka; Marta Olejniczak
Journal:  Cells       Date:  2022-02-02       Impact factor: 6.600

8.  De novo mutations in ataxin-2 gene and ALS risk.

Authors:  José Miguel Laffita-Mesa; Jorge Michel Rodríguez Pupo; Raciel Moreno Sera; Yaimee Vázquez Mojena; Vivian Kourí; Leonides Laguna-Salvia; Michael Martínez-Godales; José A Valdevila Figueira; Peter O Bauer; Roberto Rodríguez-Labrada; Yanetza González Zaldívar; Martin Paucar; Per Svenningsson; Luís Velázquez Pérez
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.